Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pandion Therapeutics stock | $16.11

Own Pandion Therapeutics stock in just a few minutes.

Fact checked

Pandion Therapeutics, Inc is a biotechnology business based in the US. Pandion Therapeutics shares (PAND) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Pandion Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Pandion Therapeutics. Find the stock by name or ticker symbol: PAND. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Pandion Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$16.11, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Pandion Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Pandion Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Pandion Therapeutics share price

Use our graph to track the performance of PAND stocks over time.

Pandion Therapeutics shares at a glance

Information last updated 2021-01-14.
Latest market closeUSD$16.11
52-week rangeUSD$10.28 - USD$27.752
50-day moving average USD$16.6314
200-day moving average USD$15.5716
Wall St. target priceUSD$25.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Pandion Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pandion Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pandion Therapeutics price performance over time

Historical closes compared with the close of $16.11 from 2020-12-09

1 week (2021-01-07) -9.60%
1 month (2020-12-16) 4.61%
3 months (2020-10-15) 42.44%
6 months (2020-07-13) N/A
1 year (2020-01-13) N/A
2 years (2019-01-13) N/A
3 years (2018-01-13) N/A
5 years (2016-01-13) N/A

Pandion Therapeutics financials

Revenue TTM USD$7.6 million
Gross profit TTM USD$967,000
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$539.9 million

TTM: trailing 12 months

Shorting Pandion Therapeutics shares

There are currently 169,410 Pandion Therapeutics shares held short by investors – that's known as Pandion Therapeutics's "short interest". This figure is 67% down from 514,108 last month.

There are a few different ways that this level of interest in shorting Pandion Therapeutics shares can be evaluated.

Pandion Therapeutics's "short interest ratio" (SIR)

Pandion Therapeutics's "short interest ratio" (SIR) is the quantity of Pandion Therapeutics shares currently shorted divided by the average quantity of Pandion Therapeutics shares traded daily (recently around 38155.405405405). Pandion Therapeutics's SIR currently stands at 4.44. In other words for every 100,000 Pandion Therapeutics shares traded daily on the market, roughly 4440 shares are currently held short.

However Pandion Therapeutics's short interest can also be evaluated against the total number of Pandion Therapeutics shares, or, against the total number of tradable Pandion Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pandion Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Pandion Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0324% of the tradable shares (for every 100,000 tradable Pandion Therapeutics shares, roughly 32 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pandion Therapeutics.

Find out more about how you can short Pandion Therapeutics stock.

Pandion Therapeutics share dividends

We're not expecting Pandion Therapeutics to pay a dividend over the next 12 months.

Pandion Therapeutics overview

Pandion Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprised of an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases. The company's other product candidates comprise PT627, a systemic PD-1 agonist that is in preclinical studies for the treatment of autoimmune diseases; PT001, a bifunctional molecule combining its PD-1 agonist effector with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM) to drive tissue-selective immunomodulation in the gastrointestinal tract; and PT002, a bifunctional molecule combining its IL-2 mutein effector with a tether module that binds to MAdCAM to drive tissue-selective immunomodulation in the gastrointestinal tract. It has a collaboration with Astellas Pharma Inc. to develop locally acting immunomodulators for autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site